Akeso Biomedical, Inc., a Waltham, Mass.-based an animal health and food safety company, raised $4.4M in funding.
Backers included existing and new investors.
The company will use the funds to develop manufacturing and global distribution partnerships for TYPLEX™ Chelate and advance other applications of its Fe3C technology.
Led by Simon Williams, CEO, and Jerome Meier, Chief Operating Officer, Akeso develops novel, non-antibiotic feed additive technologies to improve food safety, animal health and production.
Its TYPLEX™ Chelate is a zootechnical gut health stabilizer which inhibits pathogenic bacteria, such as Clostridium, Campylobacter, Salmonella and E. coli from adhering to avian gut walls. Use of TYPLEX Chelate as a feed additive has been shown in trials to result in an improved gut microbiome in broilers, allowing better nutrient absorption and leading to better performance in the grow-out of chickens, without the use of antibiotics.
The company is also advancing other applications of its Fe3C technology in animal health, including improvements in weaner piglet health, welfare, performance and gut microflora.
Akeso Biomedical is a VIC Technology Venture Development™ portfolio company.